VCYT Q3 2022 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$76M+25.2% YoY

Gross Profit

$50M65.6% margin

Operating Income

-$10M-12.8% margin

Net Income

-$9M-11.5% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+3.7%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$5M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$78M

Stockholders' Equity

$1.0B

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$60M	+25.2%
Gross Profit	$50M	$39M	+28.0%
Operating Income	-$10M	-$17M	+42.0%
Net Income	-$9M	-$14M	+38.3%

Revenue Segments

Testing

$65M85%

Biopharmaceutical And Other

$8M10%

Product

$3M4%